Sinopharm leading COVID-19 vaccine race among Chinese pharmaceutical companies: Report

Out of five experimental shots for coronavirus vaccine produced by Chinese pharmaceutical companies that have w reached st of human trials, Sipharm Group Co is leing race. According to international media reports, Sipharm has been leing race of developing COVID-19 vaccine by vastest difference since April 2015 and is w a prominent healthcare name attracting investors to sector. Meanwhile, global coronavirus infections have w surpassed 8.1 million with 444,368 deaths as per Johns Hopkins University tally, and China is also fearing second wave of COVID-19 pandemic with definite vaccine of fatal disease yet.

According to Weibo posting of a unit of Sinpharm’s parent company, China National Biotec Group on June 16, vaccine candidate developed by Sipharm’ Institute of Biological Products Co in Wuhan has reportedly t shown any unfavourable reactions in both phases I and II of clinical trials. This vaccine developed by Sipharm has been me by using a killed version of vel coronavirus that is SARS-CoV-2. w, it will be subjected to human trials before it is approved for use of public amid global health crisis. 

Re - France Pledges Funding UK Begins Coronavirus Vaccine Trial

Re - US Expects Insurers To Cover COVID Vaccine Without Copays

Three out five have shown positive outcome

According to outcome of early phases of human trial, three out of five vaccines put toger by Chinese pharmaceutical companies are deemed safe and are able to evoke individual’s immune system. se studies reportedly included hundreds of human volunteers. 

International media reports have stated that positive response of Sipharm’s vaccine candidate has boosted company’s shares by 15 per cent in Hong Kong to emerge as ‘best performer’ in MSCI Asia Pacific Index. 

Moreover, China National Medicines Corp has also spiked by ten per cent daily limit in Shanghai and ar unit of Sipharm, China National Accord Medicines Corp surged at least 8.8 per cent in Shenzhen. MSCI China healthcare gauge has also spiked as much as 2.2 per cent to highest in two years, according to international media report. 

Re - AstraZeneca's Potential Coronavirus Vaccine Likely To Provide Protection For A Year

Re - Experts Warn COVID-19 Vaccines Might Be Ineffective, Come With 'limitation'

Im: Representational/Pixabay